An investigational oral agent known as MDV-3100, which halts androgen signaling, may significantly improve survival in men with metastatic castration-resistant prostate cancer (CRPC). John Schieszer reports in today’s Medical Minute that this agent may change the treatment paradigm for men with metastatic prostate cancer.